Top

Targeted Oncology

Published in:

01-12-2015 | Original Research Article

The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX

Authors: Yufeng Wang, Yasuhiro Kuramitsu, Takao Kitagawa, Kazuhiro Tokuda, Byron Baron, Junko Akada, Kazuyuki Nakamura

Published in: Targeted Oncology | Issue 4/2015

Abstract

Background

Gemcitabine (GEM) remains a major chemotherapeutic drug for pancreatic cancer, but resistance to GEM has been a big problem, as its response rate has been decreasing year by year.

Methods

The effect of the histone deacetylase inhibitor (HDAI) valproic acid (VPA) was compared with tranilast and RI-1 as a combinatorial treatment with GEM in four pancreatic cancer cell lines, BxPC-3, PK45p, MiaPaCa-2 and PK59. Cell viability assays were carried out to check the cytotoxic effects, western blotting was carried out for DNA repair mechanisms, and localization was determined by immunofluorescence.

Results

The sensitization factors (i.e., the fold ratio of cell viability for GEM/GEM plus drug) reveal that VPA increases the cytotoxic sensitization to GEM at approximately 2.7-fold, 1.2-fold, 1.5-fold and 2.2-fold in BxPC-3, MiaPaCa-2, PK-45p and PK-59 cell lines, respectively. Moreover, GEM induces activation of the DNA repair protein H2AX proportional to the dosage. Interestingly, however, this effect can be abrogated by VPA.

Conclusions

These results indicate that VPA enhances GEM-induced cytotoxicity in GEM-resistant pancreatic cancer cells, possibly through inhibition of DNA damage signaling and repair. Our study suggests VPA as a potential therapeutic agent for combinatorial treatment with GEM in pancreatic cancer.

Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Mikuria K, Fujimoto M, Maehara S et al (2007) Proteomics finding heat shock protein 27 as a biomarker for resistance of pancreatic cancer cells to gemcitabine. Int J Oncol 31:1345–50PubMed

Mori-Iwamoto S, Kuramitsu Y, Ryozawa S, Taba K, Fujimoto M, Okita K et al (2008) A proteomic profiling of gemcitabine resistance in pancreatic cancer cell lines. Mol Med Rep 1:429–34PubMed

Taba K, Kuramitsu Y, Ryozawa S, Yoshida K, Tanaka T, Mori-Iwamoto S et al (2011) KNK437 downregulates heat shock protein 27 of pancreatic cancer cells and enhances the cytotoxic effect of gemcitabine. Chemotherapy 57:12–6CrossRefPubMed

Kuramitsu Y, Wang Y, Taba K, Suenaga S, Ryozawa S, Kaino S et al (2012) Heat-shock protein 27 plays the key role in gemcitabine-resistance of pancreatic cancer cells. Anticancer Res 32:2295–9PubMed

Baker CH, Banzon J, Bollinger JM, Stubbe J, Samano V, Robins MJ et al (1991) 2′-Deoxy-2′-methylenecytidine and 2′-deoxy-2′,2′-difluorocytidine 5′-diphosphates: potent mechanism-based inhibitors of ribonucleotide reductase. J Med Chem 34:1879–84CrossRefPubMed

Huang P, Chubb S, Hertel LW, Grindey GB, Plunkett W (1991) Action of 2′,2′-difluorodeoxycytidine on DNA synthesis. Cancer Res 51:6110–7PubMed

Karnitz LM, Flatten KS, Wagner JM, Loegering D, Hackbarth JS, Arlander SJ et al (2005) Gemcitabine-induced activation of checkpoint signaling pathways that affect tumor cell survival. Mol Pharmacol 68:1636–44PubMed

Matthews DJ, Yakes FM, Chen J, Tadano M, Bornheim L, Clary DO et al (2007) Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle 6:104–10CrossRefPubMed

Parsels LA, Morgan MA, Tanska DM, Parsels JD, Palmer BD, Booth RJ et al (2009) Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells. Mol Cancer Ther 8:45–54PubMedCentralCrossRefPubMed

10.

Činčárová L, Zdráhal Z, Fajkus J (2013) New perspectives of valproic acid in clinical practice. Expert Opin Investig Drugs 22:1535–47CrossRefPubMed

11.

Rajendran P, Ho E, Williams DE, Dashwood RH (2011) Dietary phytochemicals, HDAC inhibition, and DNA damage/repair defects in cancer cells. Clin Epigenetics 3:4PubMedCentralCrossRefPubMed

12.

Kachhap SK, Rosmus N, Collis SJ, Kortenhorst MS, Wissing MD, Hedayati M et al (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One 5, e11208PubMedCentralCrossRefPubMed

13.

Chen X, Wong P, Radany E, Wong JY (2009) HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells. Cancer Biother Radiopharm 24:689–99PubMedCentralCrossRefPubMed

14.

Noguchi H, Yamashita H, Murakami T, Hirai K, Noguchi Y, Maruta J et al (2009) Successful treatment of anaplastic thyroid carcinoma with a combination of oral valproic acid, chemotherapy, radiation and surgery. Endocr J 56:245–9CrossRefPubMed

15.

Masoudi A, Elopre M, Amini E, Nagel ME, Ater JL, Gopalakrishnan V et al (2008) Influence of valproic acid on outcome of high-grade gliomas in children. Anticancer Res 28:2437–42PubMed

16.

Candelaria M, Cetina L, Pérez-Cárdenas E, de la Cruz-Hernández E, González-Fierro A, Trejo-Becerril C et al (2010) Epigenetic therapy and cisplatin chemoradiation in FIGO stage IIIB cervical cancer. Eur J Gynaecol Oncol 31:386–91PubMed

17.

Kamrava M, Citrin D, Sproull M, Lita E, Smith S, Sears-Crouse N et al (2008) Acute toxicity in a phase II clinical trial of valproic acid in combination with Temodar and radiation therapy in patients with glioblastoma multiforme. Int J Radiat Oncol Biol Phys 72:S211CrossRef

18.

Kwan P, Brodie MJ (2001) Effectiveness of first antiepileptic drug. Epilepsia 42(10):1255–60CrossRefPubMed

19.

Meek K, Dang V, Lees-Miller SP (2008) DNA-PK: the means to justify the ends? Adv Immunol 99:33–58CrossRefPubMed

20.

Buisson R, Dion-Côté AM, Coulombe Y, Launay H, Cai H, Stasiak AZ et al (2010) Cooperation of breast cancer proteins PALB2 and piccolo BRCA2 in stimulating homologous recombination. Nat Struct Mol Biol 17:1247–54PubMedCentralCrossRefPubMed

21.

Pellegrini L, Yu DS, Lo T, Anand S, Lee M, Blundell TL et al (2002) Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 420:287–93CrossRefPubMed

22.

Trapp O, Seeliger K, Puchta H (2011) Homologs of breast cancer genes in plants. Front Plant Sci 2:19PubMedCentralCrossRefPubMed

23.

Sharma A, Singh K, Almasan A (2012) Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 920:613–26CrossRefPubMed

24.

Cheng YC, Lin H, Huang MJ, Chow JM, Lin S, Liu HE (2007) Downregulation of c-Myc is critical for valproic acid-induced growth arrest and myeloid differentiation of acute myeloid leukemia. Leuk Res 31:1403–11CrossRefPubMed

25.

Schuchmann M, Schulze-Bergkamen H, Fleischer B, Schattenberg JM, Siebler J, Weinmann A et al (2006) Histone deacetylase inhibition by valproic acid down-regulates c-FLIP/CASH and sensitizes hepatoma cells towards CD95- and TRAIL receptor-mediated apoptosis and chemotherapy. Oncol Rep 15:227–30PubMed

26.

Ziauddin MF, Yeow WS, Maxhimer JB, Baras A, Chua A, Reddy RM (2006) Valproic acid, an antiepileptic drug with histone deacetylase inhibitory activity, potentiates the cytotoxic effect of Apo2L/TRAIL on cultured thoracic cancer cells through mitochondria-dependent caspase activation. Neoplasia 8:446–57PubMedCentralCrossRefPubMed

27.

Greenblatt DY, Cayo MA, Adler JT, Ning L, Haymart MR, Kunnimalaiyaan M et al (2008) Valproic acid activates Notch1 signaling and induces apoptosis in medullary thyroid cancer cells. Ann Surg 247:1036–40PubMedCentralCrossRefPubMed

28.

Lampen A, Siehler S, Ellerbeck U, Göttlicher M, Nau H (1999) New molecular bioassays for the estimation of the teratogenic potency of valproic acid derivatives in vitro: activation of the peroxisomal proliferator-activated receptor (PPARdelta). Toxicol Appl Pharmacol 160:238–49CrossRefPubMed

29.

Togi S, Kamitani S, Kawakami S, Ikeda O, Muromoto R, Nanbo A et al (2009) HDAC3 influences phosphorylation of STAT3 at serine 727 by interacting with PP2A. Biochem Biophys Res Commun 379:616–20CrossRefPubMed

30.

Stamatopoulos B, Meuleman N, De Bruyn C, Mineur P, Martiat P, Bron D et al (2009) Antileukemic activity of valproic acid in chronic lymphocytic leukemia B cells defined by microarray analysis. Leukemia 23:2281–9CrossRefPubMed

31.

Spiecker M, Lorenz I, Marx N, Darius H (2002) Tranilast inhibits cytokine-induced nuclear factor kappaB activation in vascular endothelial cells. Mol Pharmacol 62:856–63CrossRefPubMed

32.

Nie L, Mogami H, Kanzaki M, Shibata H, Kojima I (1996) Blockade of DNA synthesis induced by platelet-derived growth factor by tranilast, an inhibitor of calcium entry, in vascular smooth muscle cells. Mol Pharmacol 50:763–9PubMed

33.

Mitsuno M, Kitajima Y, Ohtaka K, Kai K, Hashiguchi K, Nakamura J et al (2010) Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol 36:341–9PubMed

34.

Ewald B, Sampath D, Plunkett W (2007) H2AX phosphorylation marks gemcitabine-induced stalled replication forks and their collapse upon S-phase checkpoint abrogation. Mol Cancer Ther 6:1239–48CrossRefPubMed

35.

Vitale G, Zappavigna S, Marra M, Dicitore A, Meschini S, Condello M et al (2012) The PPAR-γ agonist troglitazone antagonizes survival pathways induced by STAT-3 in recombinant interferon-β treated pancreatic cancer cells. Biotechnol Adv 30:169–84CrossRefPubMed

36.

Mackenzie GG, Huang L, Alston N, Ouyang N, Vrankova K, Mattheolabakis G et al (2013) Targeting mitochondrial STAT3 with the novel phospho-valproic acid (MDC-1112) inhibits pancreatic cancer growth in mice. PLoS One 8, e61532PubMedCentralCrossRefPubMed

37.

Koga H, Selvendiran K, Sivakumar R, Yoshida T, Torimura T, Ueno T et al (2012) PPARγ potentiates anticancer effects of gemcitabine on human pancreatic cancer cells. Int J Oncol 40:679–85PubMed

Title: The Histone Deacetylase Inhibitor Valproic Acid Sensitizes Gemcitabine-Induced Cytotoxicity in Gemcitabine-Resistant Pancreatic Cancer Cells Possibly Through Inhibition of the DNA Repair Protein Gamma-H2AX
Authors: Yufeng Wang
Yasuhiro Kuramitsu
Takao Kitagawa
Kazuhiro Tokuda
Byron Baron
Junko Akada
Kazuyuki Nakamura
Publication date: 01-12-2015
Publisher: Springer International Publishing
Published in: Targeted Oncology / Issue 4/2015
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI: https://doi.org/10.1007/s11523-015-0370-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 4/2015

The Association of Serum Carcinoembryonic Antigen, Carbohydrate Antigen 19-9, Thymidine Kinase, and Tissue Polypeptide Specific Antigen with Outcomes of Patients with Metastatic Colorectal Cancer Treated with Bevacizumab: a Retrospective Study

Detection of KIT and PDGFRA mutations in the plasma of patients with gastrointestinal stromal tumor

Acknowledgment to Referees

Renal Toxicities of Targeted Therapies

Antisense inhibition of microRNA-21 and microRNA-221 in tumor-initiating stem-like cells modulates tumorigenesis, metastasis, and chemotherapy resistance in pancreatic cancer

Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer